Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-358-3 | CAS number: 2736-23-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Case report with number of subjects limited. Only two patients were exposed to the substance.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 007
Materials and methods
- Type of sensitisation studied:
- respiratory
- Study type:
- case report
Test guideline
- Qualifier:
- no guideline available
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 2,4-dichloro-5-sulphamoylbenzoic acid
- EC Number:
- 220-358-3
- EC Name:
- 2,4-dichloro-5-sulphamoylbenzoic acid
- Cas Number:
- 2736-23-4
- Molecular formula:
- C7H5Cl2NO4S
- IUPAC Name:
- 2,4-dichloro-5-sulphamoylbenzoic acid
- Details on test material:
- - Name of test material (as cited in study report): 2,4-dichloro-5-sulfamoylbenzoic acid (lasamide)
- Molecular weight (if other than submission substance): 270.09 g/mol.
- State: white crystalline powder
Constituent 1
Method
- Type of population:
- occupational
- Ethical approval:
- confirmed and informed consent free of coercion received
- Remarks:
- All of the examinations and tests were approved by the Ethics Committee of the 1st Faculty of Medicine, Charles University, Prague, and all persons enrolled in this study provided their written informed consent for all of the tests.
- Subjects:
- - Number of subjects exposed: 5 patients from a lasamide production line with suspected occupational asthma and rhinitis.
- Sex: male
- Age: Patient 1: 54 years
Patient 2: 57 years
Patient 3: 46 years
Patient 4 and 5: 30 years
- Demographic information: Czech Republic
- Others: Patient 1, 2, 3 and 5 are ex-smoker, patient 4 is nonsmoker.
Patient 1, 2 and 3 only tested with 2,4-dichloro-5-chlorsulfonylbenzoic acid.
Patient 4 was tested with lasamide in the form of both dried powder (final product) and raw paste (product prior to drying), 2,4-dichlorobenzoic acid and 2,4-dichloro-5-chlorsulfonylbenzoic acid.
Patient 5 was assayed with the same compounds as patient 4 with the exception of 2,4-dichlorobenzoic acid. - Clinical history:
- Patient 1: had worked in the chemical industry for 15 years and for 4 years mainly on the lasamide production line. His health problems (sneezing, rhinorrhea,cough, and dyspnea) started 3 years after beginning his work on the lasamide line. At the time of diagnosis, he tested positive for total IgE, negative in the skin prick test and negative in the nonspecific bronchoprovocation test. Positive in a specific bronchoprovocation test : positive occupational asthma + occupational rhinitis (significant decrease of FEV 1 and nasal flow, symptoms).
Patient 2: had worked in the chemical industry for 32 years and for 4 years mainly on the lasamide production line. Sneezing and rhinorrhea started 2.5 years after he began work with lasamide and its precursors, with dyspnea and wheezing observed half a year later.
Total IgE and skin prick tests: negative at the time of diagnosis. Nonspecific bronchoprovocation test: positive at the time of diagnosis.
Specific bronchoprovocation test: bordeline. Positive occupational asthma + occupational rhinitis (significant increase in total respiratory resistance plus symptoms, significant decrease in nasal flow plus symptoms of rhinitis).
Patient 3: had worked in the chemical industry for 5.5 years mainly on the lasamide production line. His health problems started after 2–3 years, with sneezingand rhinorrhea, followed by dyspnea, wheezing and cough.
Specific bronchoprovocation test: positive=positive occupational asthma + occupational rhinitis (significant decrease of FEV 1, serious symptoms of rhinitis).
Total IgE, skin prick tests and the nonspecific bronchoprovocation test: positive at the time of diagnosis.
Patient 4: had worked in the chemical industry for 9 years and for 5.5 years mainly on the lasamide production line. Rhinorrhea, nasal blockage and conjunctivitis developed after 4–5 years, followed by dyspnea and cough half a year later. Because of these persisting health problems, the patient was removed from theworkplace.
Nonspecific bronchoprovocation test and skin prick tests: positive at the time of the diagnosis. Total IgE: negative.
Specific bronchoprovocation test: negative but it was observed reduced nasal flow and symptoms of rhinitis.
Patient 5: had worked in the chemical industry for 10 years and for 5 years mainly on the lasamide production line. Conjunctivitis, rhinorrhea, cough, and dyspnea started after 2–3 years.
Total IgE and skin prick tests: positive at the time of the diagnosis. Nonspecific bronchoprovocation test: not performed at the time of diagnosis.
Specific bronchoprovocation test: negative but symptoms of rhinitis, reduced nasal flow in the test with 2,4-dichloro-5-chlorsulfonylbenzoic acid. - Controls:
- Control tests with a placebo (sodium chloride).
- Route of administration:
- inhalation
- Details on study design:
- During the first hospitalization, the following parameters were determined, and the following tests were performed:
- Total immunoglobulin E (IgE)
- Skin prick test with environmental allergens
- Nonspecific bronchoprovocation tests and specific bronchoprovocation tests with the suspected occupational allergens
- Control tests with a placebo (sodium chloride).
At follow-ups (1–3 years after removal from occupational allergen exposure) all of the examinations, except the specific bronchoprovocation tests, were performed again.
- Skin prick test (Sevapharma, Czech Republic) were done with common environmental respiratory allergens (dust, feathers, mites, pollen–grass, spring and autumn mixture, molds, upper respiratory tract bacteria).
- Spirometry and body plethysmography
- Nonspecific bronchoprovocation tests: first performed with acetylcholine (at concentrations of 1, 2.5, and 10 or 5 mg/ml) for two patients and later with histamine (at concentrations of 1, 5, and 10 mg/ml), using the Asthma Provocation System (APS) Jaeger (dosimeter method).
- Specific bronchoprovocation tests: performed with the compounds used in the lasamide production and suspected of causing asthma or rhinitis.
Results and discussion
- Results of examinations:
- At follow-ups 1–3 years after removal from occupational allergen exposure:
Patient 1: Total IgE and skin prick test: negative; nonspecific bronchoprovocation : positive only at follow-up 1.
Patient 2: Total IgE and skin prick test: negative; nonspecific bronchoprovocation : positive at follow-up 2.
Patient 3: Total IgE and nonspecific bronchoprovocation: positive; skin prick test : positive at follow-up 1.
Patient 4: Total IgE negative and skin prick test positive; nonspecific bronchoprovocation negative.
patient 5: Total IgE and skin prick test: positive; nonspecific bronchoprovocation: negative.
Patients which were exposed to Lasamide (dried or raw) suffered of rhinitis at the time of diagnosis.
The allergic symptoms did not resolve for any of our patients after removal from occupational allergen exposure, and four of the five patients received medication to control their diseases.
Applicant's summary and conclusion
- Conclusions:
- The reported cases indicate that lasamide and 2,4-dichloro-5-chlorsulfonylbenzoic acid may cause occupational asthma and rhinitis.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.